Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sharp & dohme (malaysia) sdn bhd - zoster vaccine live oka/merck -

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - interferon alfa-2b -

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - interferon alfa-2b -

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - interferon alfa-2b -

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - interferon alfa-2b -

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - interferon alfa-2b -

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - interferon alfa-2b -

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - varicella vaccine 1350 pfu (oka/merck);   - injection with diluent - 1350 pfu - active: varicella vaccine 1350 pfu (oka/merck)   excipient: dibasic sodium phosphate dodecahydrate gelatin monobasic potassium phosphate monosodium glutamate potassium chloride sodium chloride sucrose urea water for injection - varivax is indicated for vaccination against varicella in individuals 12 months of age and older.

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - live attenuated oka/merck strain of varicella-zoster virus - powder and solvent for suspension for injection - live attenuated oka/merck strain of varicella-zoster virus 19400 pfu / 0.65 ml - zoster, live attenuated - zoster, live attenuated - zostavax is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - hydrochlorothiazide 12.5mg;  ;  ; losartan potassium 50mg;   - film coated tablet - 50mg/12.5mg - active: hydrochlorothiazide 12.5mg     losartan potassium 50mg   excipient: carnauba wax hyprolose hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose quinoline yellow starch titanium dioxide - hypertension hyzaar is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy hyzaar is a combination of losartan (cozaar) and hydrochlorothiazide. in patients with hypertension and left ventricular hypertrophy, losartan, often in combination with hydrochlorothiazide, reduces the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy.